It is reported that lenvatinib reduces Treg cell infiltration and activates immune pathways, resulting in reprograming of the tumor microenvironment, which may contribute to improvement of the efficacy of anti-PD-1 therapy [15, 16]. This evidence concerns the gene PDCD1 and neoplasm.